COVID-19 Vaccines approved by WHO.
                     COVID-19 VACCINES 
APPROVED BY WHO
Introduction
• While COVID-19 vaccine supplies are limited, health workers at high risk of 
exposure and older people should be prioritised for vaccination.
• Countries can refer to the WHO Prioritization Roadmap and the WHO Values 
Framework as guidance for their prioritisation of target groups.
Source: www.who.int
Who should be vaccinated first?
• While COVID-19 vaccine supplies are limited, health workers at high risk of 
exposure and older people should be prioritised for vaccination.
• Countries can refer to the WHO Prioritization Roadmap and the WHO Values 
Framework as guidance for their prioritisation of target groups.
Source: www.who.int
WHO emergency use listing 
• The emergency use listing (EUL) procedure assesses the suitability of novel health 
products during public health emergencies. 
• The objective is to make medicines, vaccines and diagnostics available as rapidly as 
possible to address the emergency, while adhering to stringent criteria of safety, efficacy 
and quality. 
Source: www.who.int
Pfizer and BioNTech's 'BNT162b2'
• It's a nucleoside modified mNRA jab. It is being administered in the United States, 
Israel and the United Kingdom, among other countries.
Source: www.moneycontrol.com
AstraZeneca and Oxford University's 'AZD1222'
• It uses the recombinant ChAdOx1 adenoviral vector encoding the spike protein 
antigen of SARS-CoV-2. It is being administered in the United Kingdom, Malaysia, 
South Korea, Mexico, the European Union, etc. 
• The same vaccine is registered separately by the Serum Institute of India (SII) as 
‘Covishield’.
Source: www.moneycontrol.com
Johnson & Johnson-Janssen's 'Ad26.COV2.S'
• This is a recombinant, replication in competent adenovirus type 26 (Ad26) 
vectored vaccine encoding the (SARS-CoV-2) spike protein. 
• It has been deployed in the United States, United Kingdom, and Switzerland, and 
European nations, among others.
Source: www.moneycontrol.com
Moderna's 'mRNA-1273'
• It is a mNRA-based vaccine encapsulated in a lipid nanoparticle (LNP). It is being 
administered in Canada, Denmark, Finland, Israel, Japan, Portugal, and Taiwan, 
among other countries.
Source: www.moneycontrol.com
Sinopharm-BBIBP's SARS-CoV-2 Vaccine
• It is an inactivated virus vaccine produced by the China National Pharmaceutical 
Group (Sinopharm) and its Beijing Institute of Biological Products. 
• It is mainly being used in China, Bahrain, Seychelles, and the United Arab 
Emirates, among some other countries.
Source: www.moneycontrol.com
Sinovac-CoronaVac
• The WHO Strategic Advisory Group of Experts (SAGE) on Immunization has issued 
Interim recommendations for the use of the inactivated COVID-19 vaccine, 
Sinovac-CoronaVac, developed by Sinovac/China National Pharmaceutical Group.
Source: www.who.int
THANK YOU